BeiGene, Ltd. (NASDAQ:BGNE) Receives Consensus Recommendation of “Moderate Buy” from Analysts

BeiGene, Ltd. (NASDAQ:BGNE) has been assigned a consensus rating of “Moderate Buy” from the seven ratings firms that are presently covering the company, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month target price among brokers that have issued a report on the stock in the last year is $247.07.

BGNE has been the subject of a number of analyst reports. StockNews.com downgraded shares of BeiGene from a “buy” rating to a “hold” rating in a research report on Thursday, November 21st. JMP Securities assumed coverage on BeiGene in a research note on Wednesday, September 18th. They issued a “market outperform” rating and a $288.00 price target for the company. JPMorgan Chase & Co. increased their price target on BeiGene from $200.00 to $235.00 and gave the stock an “overweight” rating in a research report on Tuesday, October 22nd. TD Cowen boosted their price objective on BeiGene from $254.00 to $260.00 and gave the company a “buy” rating in a research report on Wednesday, November 13th. Finally, Citigroup increased their target price on BeiGene from $269.00 to $288.00 and gave the company a “buy” rating in a research report on Thursday, August 8th.

BeiGene Stock Up 4.3 %

BeiGene stock opened at $215.00 on Friday. BeiGene has a 52 week low of $126.97 and a 52 week high of $248.16. The firm has a market cap of $20.94 billion, a price-to-earnings ratio of -26.09 and a beta of 0.63. The business’s 50-day moving average price is $212.42 and its 200 day moving average price is $184.46. The company has a quick ratio of 1.72, a current ratio of 1.93 and a debt-to-equity ratio of 0.05.

BeiGene (NASDAQ:BGNE) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($1.15) EPS for the quarter, missing analysts’ consensus estimates of ($1.11) by ($0.04). BeiGene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The firm had revenue of $1 billion for the quarter, compared to analyst estimates of $983.26 million. During the same period in the previous year, the business earned $2.01 EPS. BeiGene’s revenue for the quarter was up 28.2% compared to the same quarter last year. As a group, sell-side analysts anticipate that BeiGene will post -5.38 earnings per share for the current year.

Insider Buying and Selling

In related news, SVP Chan Henry Lee sold 1,202 shares of the business’s stock in a transaction dated Monday, September 30th. The shares were sold at an average price of $237.10, for a total transaction of $284,994.20. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Xiaobin Wu sold 5,556 shares of the stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $189.65, for a total transaction of $1,053,695.40. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 63,538 shares of company stock worth $12,594,017. 7.43% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On BeiGene

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Blue Trust Inc. raised its holdings in shares of BeiGene by 156.3% during the 3rd quarter. Blue Trust Inc. now owns 123 shares of the company’s stock worth $28,000 after acquiring an additional 75 shares during the period. Allspring Global Investments Holdings LLC acquired a new stake in BeiGene during the third quarter worth about $36,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in BeiGene during the third quarter worth about $67,000. SG Americas Securities LLC acquired a new position in BeiGene in the 3rd quarter valued at about $105,000. Finally, PFG Investments LLC purchased a new stake in shares of BeiGene in the 3rd quarter valued at approximately $210,000. Institutional investors and hedge funds own 48.55% of the company’s stock.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.